Top Markets
Coin of the day
Autolus Therapeutics plc Autolus Therapeutics plc

Autolus Therapeutics plc

AUTL
Pozycja w akcjach #12091
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily... Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Cena akcji
$2.34
Ostatnia synchronizacja: 2026-08-28
Kapitalizacja rynkowa
$621.44M
Zmiana (1 dzień)
-1.06%
Zmiana (1 rok)
55.67%
Kraj
GB
Handel Autolus Therapeutics plc (AUTL)

Kategoria

Historia ceny akcji dla Autolus Therapeutics plc (AUTL)
Najwyższa cena zamknięcia: $2.28 dnia 2026-08-01

Najniższa cena zamknięcia: $26.43 dnia 2018-06-01
Historia cen akcji firmy Autolus Therapeutics plc od 2018 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2026 (TTM) -2.43%
2025 -37.78%
2024 -48.76%
2023 131.99%
2022 -61.84%
2021 -37.82%
2020 -34.48%
2019 -57.61%
2018 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.36 -12.82%
AU
$138.18 473.58%
US
$759.27 7.20%
CH